Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Fineline Cube Jun 8, 2026
Company Drug

Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments

Fineline Cube Jun 5, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...

Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026

Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...

Company Drug

Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure

Fineline Cube Jun 5, 2026

Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Drug

Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA

Fineline Cube Jun 5, 2026

Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase...

Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026

Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...

Company Drug

Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure

Fineline Cube Jun 5, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Medical Device

GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan

Fineline Cube Jun 5, 2026

GE HealthCare (NASDAQ: GEHC) announced it has received 510(k) clearance from the United States Food...

Company Drug

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Fineline Cube Jun 4, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Fineline Cube Jun 4, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced positive results from the Phase II JASMINE study...

Company Deals

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Fineline Cube Jun 4, 2026

H. Lundbeck A/S (OTCMKTS: HLUBF) announced on June 3, 2026, a strategic partnership with Cradle,...

Company Drug

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy

Fineline Cube Jun 4, 2026

Novo Nordisk A/S (NYSE: NVO) announced the market launch of Wegovy (semaglutide) oral tablets in...

Company Deals Medical Device

Medtronic Makes Strategic ICE Catheter Investments to Strengthen Cardiac Ablation Leadership and Affera Ecosystem Integration

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, strategic investments in two privately held...

Company Deals

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Fineline Cube Jun 4, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has significantly expanded its collaboration with fellow US biotechnology company...

Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Fineline Cube Jun 4, 2026

Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...

Company Medical Device

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced on June 3, 2026, the submission of 510(k) premarket notifications...

Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Fineline Cube Jun 4, 2026

Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced...

Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Fineline Cube Jun 4, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received clinical...

Company

Medtronic Reports Strong Q4 and FY26 Results with 6.6% Organic Growth, Cardiac Ablation Solutions Surge 78%

Fineline Cube Jun 4, 2026

Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year...

Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Fineline Cube Jun 4, 2026

The U.S. Food and Drug Administration (FDA) released draft guidance on June 2, 2026, designed...

Policy / Regulatory

China’s National Health Commission Unveils Ambitious Plan for Community Health Service Expansion by 2030

Fineline Cube Jun 4, 2026

China’s National Health Commission (NHC) has released the “Notice on Further Improving the Urban Community...

Posts pagination

1 2 3 … 679

Recent updates

  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
  • Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3
  • Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II
  • Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data
  • Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Company Drug

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Company Drug

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.